Nektar Therapeutics [NKTR] stock is trading at $1.03, down -9.65%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NKTR shares have gain 7.18% over the last week, with a monthly amount glided 1.98%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nektar Therapeutics [NASDAQ: NKTR] stock has seen the most recent analyst activity on January 08, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $4. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 10, 2024, and set its price target to $6.50. On November 04, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $7 on the stock. Rodman & Renshaw initiated its recommendation with a Buy and recommended $2 as its price target on June 28, 2024. In a note dated November 09, 2023, TD Cowen upgraded an Outperform rating on this stock.
Nektar Therapeutics [NKTR] stock has fluctuated between $0.48 and $1.93 over the past year. Currently, Wall Street analysts expect the stock to reach $16.75 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $1.03 at the most recent close of the market. An investor can expect a potential return of 1526.21% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
Nektar Therapeutics [NASDAQ:NKTR] reported sales of 93.14M for the trailing twelve months, which represents a drop of -0.08%. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -1.46%, Pretax Profit Margin comes in at -1.81%, and Net Profit Margin reading is -1.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -1.74 and Total Capital is -0.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9933 points at the first support level, and at 0.9567 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0933, and for the 2nd resistance point, it is at 1.1567.
Ratios To Look Out For
For context, Nektar Therapeutics’s Current Ratio is 4.24. Also, the Quick Ratio is 4.24, while the Cash Ratio stands at 0.45. Considering the valuation of this stock, the price to sales ratio is 2.04, the price to book ratio is 3.89.
Transactions by insiders
Recent insider trading involved Wilson Mark Andrew, Chief Legal Officer, that happened on Dec 23 ’24 when 33402.0 shares were sold. Chief Legal Officer, Wilson Mark Andrew completed a deal on Dec 24 ’24 to sell 16560.0 shares. Meanwhile, Officer Wilson Mark Andrew bought 16560.0 shares on Dec 24 ’24.
